CareLit Fachartikel

Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates

N.N. · Klinische Pädiatrie · 2017 · Heft 05 · S. 259-260

Dokument
1025699
CareLit-ID
Jahr
2017
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Klinische Pädiatrie
Autor:innen
N.N.
Ausgabe
Heft 05 / 2017
Jahrgang 229
Seiten
259-260
Erschienen: 2017-09-01 00:00:00
ISSN
0300-8630
DOI
10.1055/s-0043-116334

Zusammenfassung

Recent data indicate that the number of children cared for respiratory syncytial virus (RSV) infections in hospitals is in the range of 50,000 to 100,000 per year in the United States 3. Major risk factors include apart from prematurity specifically below 29 weeks, congenital heart defects, Down syndrome and further congenital anomalies. The American Academy of Pediatrics recommended in 2014 a restriction of Palivizumab prophylaxis to preterm infants of

Schlagworte

Congenital Apart Weeks Heart Defects Anomalies Palivizumab Prophylaxis Respiratory Syncytial Virus Infections Klinische Pädiatrie